Sun Pharmaceutical Industries (SUNPHARMA) announced that the FDA has accepted for review the supplemental Biologics License Application for ILUMYA for the treatment of adults with active psoriatic arthritis. The FDA regulatory action date is expected by October 29, 2026. The sBLA is based on the results from the INSPIRE-1 and INSPIRE-2 Phase 3 clinical studies.
The company noted that if approved, this would mark a new indication for ILUMYA following its US FDA approval in 2018 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
At last close, Sun Pharma was trading at INR 1,776.00, down 1.42%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.